Epidiolex

On September 26, a marijuana-based childhood epilepsy drug took a step closer to winning approval when its maker announced promising phase 3 clinical trial results. [1]
Justin Gover, CEO of the British biotech company GW Pharmaceuticals, said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite using the medication, the young participants still experienced 3 seizures a day, approximately 90 a month. Said Gover:

Researchers are continuously finding that an oil derived from the cannabis plant is actually incredibly effective in treating and controlling a rare form of epilepsy. Since an estimated 30,000 Americans live with the particular form of this disease, this relatively recent discovery brings new hope to tens of thousands of people in helping them to regain control of their lives.

A 120-patient trial showed patients taking cannabis-based Epidiolex were able to reduce their convulsive seizures by 39 percent.
The post New Cannabis Drug Able to Reduce Seizures by 39% for Some Epilepsy Patients appeared first on The Anti-Media.

GW Pharmaceuticals is expected to be given a green light for a cannabidiol drug (marijuana-based medicine) which has shown promise in the treatment of epileptic children, cutting epileptic attacks down by as much as 100% (45% average). When will the Feds admit cannabis is a medical miracle?